Title
Category
Credits
Event date
Cost
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
This clinical brief, adapted from a 15th CMHC Annual meeting session, will cover a concise overview of the efficacy and safety of metabolic surgery in reducing cardiometabolic risk across BMI levels.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Diabetes increases the risk of cardiovascular and thrombotic adverse events in patients with CAD compared to patients with these conditions and no concomitant diabetes.  As such, current antiplatelet therapy to prevent adverse events in these high-risk patients may not be adequate, and several recently-completed and ongoing clinical trials are evaluating the efficacy and safety of additional approaches, including the use of more aggressive and specific antithrombotic agents in this setting. 
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Hyperkalemia is a serious condition associated with increased risk of mortality and is frequently prevalent and recurrent in patients who suffer from heart failure (HF), chronic kidney disease (CKD), and/or hypertension (HTN). Comorbid illnesses and use of medicines that are important for kidney and cardiac outcomes but elevate potassium levels can also increase the chronic risk for hyperkalemia.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Current evidence supports post-prandial glucose (PPG) control as an important strategy to consider in the comprehensive management plan of individuals with diabetes.  However, managing PPG remains one of the most challenging aspects of diabetes care.
  • LivDerm
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
The treatment of Atopic Dermatitis (AD) is a clinical challenge. Current treatment regimens are not curative, and patients and caregivers are frequently dissatisfied with and poorly adherent to treatment (O’Toole 2013; Snyder 2015).  The chronic nature of AD demands that clinicians be able to create flexible long-term treatment plans that evolve according to patient need. As more is understood about the disease, it has become apparent that not all forms of AD are epidemiologically and/or clinically equal (Malajian 2015).
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
While a substantial body of research demonstrates the need to address the global epidemic of metabolic syndrome, and the constellation of associated cardiometabolic risk factors simultaneously, the majority of them are still treated as separate entities.The engaging and interactive session recordings from this Masterclass cover experts across specialties on the current state of affairs and advances in cardiometabolic disease including team based-care, telemedicine, cardio-renal risk reduction, obesity management, and much more.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
The increasing rates of obesity, diabetes, and metabolic syndrome in the United States are leading to more cases NAFLD and NASH, which are now being encountered at a greater frequency in clinical practice. NASH can lead to significant morbidity and mortality, including liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC)—in fact, HCC caused by NASH is poised to become the leading cause of liver transplants in the US.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
The rapid rise of cardiometabolic disease and risk factors in children and adolescents is a huge cause of concern now and in the future. According to the CDC, close to 14 million children and adolescents aged 2-19 years have obesity in the US, with the prevalence increasing by more than 33% in the last two decades. In turn, this increase in obesity is strongly associated with increased rates of hypertension, dyslipidemia, type 2 diabetes, as well as increased overall cardiovascular risk in the pediatric population.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
During this activity, experts will discuss the rationale and clinical trial data for the use of non-steroidal mineralocorticoid receptor antagonists (MRAs) in patients with diabetic kidney disease (DKD), as well as the interpretation of these data and their potential application to patient care.This activity is part of the DKD Digital Highlights Hub.
  • LivDerm
  • TME
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Psoriasis is a chronic and inflammatory skin disease with potential systemic implications that affects 7.5 million people in the United States (Bhushan 2016; Soleymani 2018) that can lead to several comorbidities, including psoriatic arthritis, obesity, metabolic syndrome, and cardiovascular disease (Soleymani 2018). Early diagnosis and treatment are crucial in managing PsA, and clinicians need to understand the impact of both skin and joint aspects of psoriasis and PsA in order to minimize impact on patients’ quality of life (QOL).

Pages